Methods for dosing an orally active 1,2,4-oxadiazole

Patent metadata

Field	Value
Publication number	US-9226919-B2
Application number	US-97406807-A
Country	US
Kind code	B2
Filing date	Oct 11, 2007
Priority date	Oct 12, 2006
Publication date	Jan 5, 2016
Grant date	Jan 5, 2016

Abstract

The present invention relates to specific doses of and dosing regimens for using a 1,2,4-oxadiazole benzoic acid compound in treating or preventing diseases associated with nonsense mutations. In particular, the invention relates to specific doses and dosing regimens for the use of 3-[5-(2-fluoro-phenyl)-[1,2,4]oxadiazol-3-yl]-benzoic acid in mammals having diseases associated with nonsense mutations.

First claim

What is claimed is:

1. A method for treating or managing a muscular dystrophy resulting from a premature stop codon in mRNA encoded by the dystrophin gene in a patient having a muscular dystrophy resulting from a premature stop codon in mRNA encoded by the dystrophin gene, comprising administering to the patient an effective amount of 3-[5-(2-fluoro-phenyl)-[1,2,4]oxadiazol-3-yl]-benzoic acid or a pharmaceutically acceptable salt thereof in three doses per day, wherein the first dose administered is in a range of from about 18 mg/kg to about 22 mg/kg, the second dose administered is in a range of from about 18 mg/kg to about 22 mg/kg and the third dose administered is in a range of from about 35 mg/kg to about 40 mg/kg, in a plurality of 24 hour time periods, wherein the second dose is administered about 6 hours after the first dose is administered, the third dose is administered about 6 hours after the second dose is administered, and the first dose for a next 24 hour time period is administered about 12 hours after the third dose was administered for a preceding 24 hour time period, and wherein a plasma concentration of 3-[5-(2-fluoro-phenyl)-[1,2,4]oxadiazol-3-yl]-benzoic acid or a pharmaceutically acceptable salt thereof in a range of about 2 μg/mL to about 20 μg/mL is maintained in said patient for a 24 hour time period.

2. The method of claim 1 , wherein the first dose, the second dose and the third dose are administered about 30 minutes after a meal.

3. The method of claim 1 , wherein said third dose administered is about 40 mg/kg.

4. The method of claim 1 , wherein the doses are administered orally.

5. The method of claim 1 , wherein the patient is a human.

6. The method of claim 5 , wherein the amount of 3-[5-(2-fluoro-phenyl)-[1,2,4]oxadiazol-3-yl]-benzoic acid or a pharmaceutically acceptable salt thereof for each of the three doses is determined by patient weight.

7. The method of claim 6 , wherein each dose amount is administered using one or more unit dosage formulations each comprising an amount in a range of from about 35 mg to about 1400 mg of 3-[5-(2-fluoro-phenyl)-[1,2,4]oxadiazol-3-yl]-benzoic acid or a pharmaceutically acceptable salt thereof.

8. The method of claim 7 , wherein the amount in each unit dosage formulation is selected from 35 mg, 50 mg, 70 mg, 100 mg, 125 mg, 140 mg, 150 mg, 175 mg, 200 mg, 250 mg, 280 mg, 300 mg, 350 mg, 400 mg, 450 mg, 500 mg, 560 mg, 600 mg, 700 mg, 750 mg, 800 mg, 900 mg 1000 mg or 1400 mg.

9. The method of claim 7 , wherein the amount in each unit dosage formulation is selected from 35 mg, 50 mg, 70 mg, 100 mg, 125 mg, 140 mg, 175 mg, 200 mg, 250 mg, 280 mg, 350 mg, 400 mg, 500 mg, 560 mg, 700 mg, 750 mg, 800 mg, 1000 mg or 1400 mg.

10. The method of claim 7 , wherein the amount in each unit dosage formulation is selected from 125 mg, 200 mg, 250 mg, 300 mg, 450 mg, 600 mg, 750 mg, 900 mg or 1000 mg.

11. The method of claim 1 , wherein the muscular dystrophy is Duchenne Muscular Dystrophy.

12. The method of claim 1 , wherein the first dose administered is about 20 mg/kg and the second dose administered is about 20 mg/kg and the third dose administered is about 40 mg/kg.

13. A method for, in a patient having Duchenne Muscular Dystrophy resulting from a premature stop codon in mRNA encoded by the dystrophin gene, increasing the expression of dystrophin, sarcoglycan or dystroglycan in the muscle of the patient, improving the upper or lower extremity myometry in the patient, decreasing the serum creatine kinase (CK) levels in the patient or improving the patient's performance of a timed ambulatory function test comprising, administering to the patient an effective amount of 3-[5-(2-fluoro-phenyl)-[1,2,4]oxadiazol-3-yl]-benzoic acid or a pharmaceutically acceptable salt thereof in three doses per day, wherein the first dose administered is in a range of from about 18 mg/kg to about 22 mg/kg, the second dose administered is in a range of from about 18 mg/kg to about 22 mg/kg and the third dose administered is in a range of from about 35 mg/kg to about 40 mg/kg.

14. A method for, in a patient having cystic fibrosis resulting from a premature stop codon in mRNA encoded by the CFTR gene, improving the patient's forced expiratory volume in one second (FEV 1 ) or forced vital capacity (FVC) in a pulmonary function test or improving the patient's nasal transepithelial potential difference (TEPD) comprising, administering to the patient an effective amount of 3-[5-(2-fluoro-phenyl)-[1,2,4]oxadiazol-3-yl]-benzoic acid or a pharmaceutically acceptable salt thereof in three doses per day, wherein the first dose administered is in a range of from about 18 mg/kg to about 22 mg/kg, the second dose administered is in a range of from about 18 mg/kg to about 22 mg/kg and the third dose administered is in a range of from about 35 mg/kg to about 40 mg/kg.

Assignees

• Hirawat Samit
• Miller Langdon
• Ptc Therapeutics Inc

Inventors

• Hirawat Samit
• Miller Langdon

Classifications

• A61P35/00

  Antineoplastic agents · CPC title

• A61P43/00

  Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00 · CPC title

• A61P9/00

  Drugs for disorders of the cardiovascular system · CPC title

• A61P37/00

  Drugs for immunological or allergic disorders · CPC title

• A61P3/10

  for hyperglycaemia, e.g. antidiabetics · CPC title